Company Overview

Samchundang Pharmaceutical, founded in 1946, is a mid-sized South Korean drugmaker focused on prescription medicines for ophthalmology and diabetes. Listed on KOSDAQ — South Korea's technology-heavy secondary exchange — the company briefly became one of the market's so-called "emperor stocks," with its share price surpassing 1m won. Yet behind that dramatic price appreciation lie persistent questions about shareholder returns and the reliability of its corporate disclosures, making it a central reference point in debates about raising governance standards across KOSDAQ.

The company holds proprietary technology in ophthalmic combination eye drops and injectable formulations. Licensing agreements with global pharmaceutical companies generated excitement comparable to that surrounding dedicated biotechnology firms. Its platform technology for GLP-1 receptor agonists — the class of drugs used to treat diabetes and obesity — propelled it into the upper ranks of KOSDAQ by market capitalisation. But while technology-transfer prospects drove the share price skyward, shareholders saw little in return. Samchundang's trajectory has become a recurring example in financial commentary of KOSDAQ's two most persistent structural weaknesses: disclosure risk and the absence of meaningful shareholder returns.

Business and Financial Performance

*Core business*

Samchundang's main business is prescription pharmaceuticals, including ophthalmic preparations, injectables, and gastrointestinal medicines. Its proprietary microneedle platform and combination eye-drop formulation technology are regarded as its most valuable pipeline assets. In recent years, the company has prominently showcased oral and injectable formulation platforms for GLP-1 receptor agonists, earning it a premium valuation more typically associated with pure-play biotech companies.

Revenue comes from two sources: domestic prescription drugs and overseas technology-licensing income. The domestic pharmaceutical business generates steady profits, but the main driver of the company's perceived value has been technology-transfer contracts and the milestone payments they promise. As these expectations were priced in well ahead of realisation, a structural gap opened up between the share price and underlying earnings.

*Financial results by year*

Year | Revenue | Operating profit | Net profit | Notes

2021 | c.165bn won | c.11bn won | c.9bn won | Steady growth in ophthalmology and diabetes

2022 | c.178bn won | c.13bn won | c.10.5bn won | Technology-transfer expectations highlighted

2023 | c.190bn won | c.15bn won | c.12bn won | GLP-1 platform attracts attention

2024 | c.210bn won | c.16bn won | c.13bn won | Crosses emperor-stock threshold; disclosure controversy begins

2025 | c.220bn won | c.15.5bn won | c.12.5bn won | Regulatory scrutiny; credibility damaged

*Figures include estimates based on regulatory filings and press reports; some unverified numbers are approximations.*

*Valuation and share price*

At the peak of excitement over GLP-1 licensing in 2024–25, Samchundang's shares crossed the 1m-won mark, conferring emperor-stock status. Critics noted, however, that on a price-to-book basis the shares carried an excessive premium even relative to large KOSDAQ biotech peers. The structural source of volatility was the persistent gap between the earnings multiples warranted by its conventional pharmaceutical business and the speculative value assigned to its pipeline.

Key Milestones in the Shareholder Value Story

*August 2025 — Shareholders overlooked as family succession takes priority*

In August 2025, financial media including Pinpoint turned a spotlight on the company's approach to shareholder returns. Reporting suggested that the controlling family, led by chief executive Jeon In-seok, had moved energetically to arrange orderly succession of the family's stake while remaining largely passive on dividends, share buybacks, and cancellations. The dividend pay-out ratio was said to be below the sector average, and the company had made virtually no share repurchases in its history. From this point, Samchundang began to be cited regularly in KOSDAQ reform discussions as a model of what not to do.

*March 2026 — Chief executive sells shares near the all-time high*

Shortly after the share price reached emperor-stock territory, regulatory filings revealed that chief executive Jeon had sold a portion of his personal holding. The company described the transaction as a private matter unrelated to business fundamentals, but the response from shareholders was scathing. While retail investors held on, the controlling shareholder was locking in gains at the top of the market — with no buyback programme or enhanced dividend to cushion those left behind. The episode is now regarded as the turning point in the company's shareholder-relations narrative.

*April 2026 — KRX disclosure committee referral triggers "Samchundang incident"*

In April 2026, the Korea Exchange's disclosure committee referred the company for formal review, sending the share price down roughly 9% in a single session. The episode immediately became known in the market as the "Samchundang incident." At its heart were questions about whether disclosures on the progress of technology-transfer negotiations accurately reflected actual contract developments. Media commentary was pointed: "The Samchundang incident has laid bare the true face of forward-looking disclosure," wrote one outlet, warning that the credibility of disclosure — a prerequisite for KOSDAQ's broader valuation-improvement programme — had been seriously damaged.

*June 2026 — Company acknowledges undervaluation; hints at buyback*

Faced with mounting shareholder anger, the company made its first public acknowledgement in June 2026 that it "recognises the undervaluation of the share price and is considering a share repurchase." Management arranged a briefing to discuss growth strategy and platform progress. The market's reception was cool: without specific figures or a timetable, a statement of "consideration" was deemed insufficient to rebuild investor confidence. Analysts noted that the company was simultaneously carrying two heavy burdens — damaged disclosure credibility and an unbroken record of neglecting shareholder returns.

Outstanding Challenges and Assessment

*Challenges*

For Samchundang to become the kind of company that KOSDAQ's valuation-improvement programme is designed to celebrate, it must address several structural problems.

Restoring disclosure credibility is the most urgent task. The Samchundang incident highlighted problems that go beyond a single company; they reflect vulnerabilities across KOSDAQ's forward-looking disclosure regime. Building a framework for accurate and timely disclosure of technology-transfer progress, milestone achievements, and clinical results is the first priority.

Shareholder returns must be institutionalised. To date, the company has stated no specific dividend pay-out target, nor announced any formal share repurchase or cancellation programme. The demand from investors is clear: move beyond one-off statements of intent and publish a formal, multi-year shareholder return plan.

Governance transparency needs to improve. The controversy over the controlling family's share sales and succession arrangements has intensified calls for a more independent board and genuine engagement with institutional investors under the stewardship code that South Korean asset managers are expected to observe.

*Assessment*

Market opinion on Samchundang is, at present, genuinely two-sided. On the positive side, the company possesses real technology — its microneedle and GLP-1 platforms are not mere concepts — and its ability to negotiate technology-transfer agreements with global pharmaceutical companies has been demonstrated. The very fact that it is mentioned as a candidate for KOSDAQ's best-in-class programme reflects a degree of recognition for its technical capabilities.

On the negative side, the Samchundang incident has embedded a deep credibility risk. The chief executive's decision to sell shares near the all-time high, at a time when the company had done almost nothing to return capital to outside shareholders, has become a symbol of the misalignment between management interests and those of minority investors. Financial analysts and journalists broadly agree that the test of whether Samchundang can evolve from cautionary tale to model company will be whether actual capital-return measures follow.

Controversies and Structural Concerns

*The structural weakness of forward-looking disclosure*

The April 2026 regulatory referral exposed problems that extend well beyond Samchundang. Technology-licensing agreements in the pharmaceutical and biotech industry routinely contain non-disclosure obligations, which place genuine limits on what companies can say publicly about contract terms. But critics argue that this structural constraint is routinely exploited to issue "wishful disclosures" that inflate market expectations without committing to specifics. Samchundang's case has become the reference example in ongoing regulatory discussions about strengthening guidelines for forward-looking statements on KOSDAQ.

*Share sales by the controlling family and the absence of investor protection*

The chief executive's share disposal near the market peak was not unlawful. But the reputational damage was severe, particularly because it occurred against a backdrop of minimal shareholder returns. The episode crystallised a grievance common among retail investors in KOSDAQ-listed family-controlled companies: management profits while outside shareholders bear the losses. It illustrates the structural tension between the owner-operated model that dominates Korean mid-cap companies and any genuine commitment to shareholder value.

*Buybacks versus restricted stock units: the risk of misdirected capital*

As of March 2026, reporting noted a growing trend across South Korea's pharmaceutical and biotech sector of companies using treasury shares for employee compensation through restricted stock unit (RSU) schemes rather than cancelling them outright. Share cancellation is widely understood to be the most direct mechanism for enhancing shareholder value under the valuation-improvement programme. How Samchundang deploys any shares it repurchases will therefore be watched as a test of whether its intentions are genuine.

*A drag on KOSDAQ's broader discount*

Market participants have argued that the Samchundang incident dealt a setback to the wider effort to close the so-called KOSDAQ discount — the persistent tendency of the exchange to trade at a lower valuation multiple than comparable markets. With foreign and institutional investors already wary, the combination of disclosure failure and absent shareholder returns risks reinforcing negative perceptions of the entire market. One outlet put it plainly: "The KOSDAQ discount cannot be closed until the Samchundang problem is resolved."

Key Metrics at a Glance

Year | DPS (won) | Pay-out ratio | Buybacks / cancellations | Operating profit | Est. P/B

2021 | c.500 | ~5% | None | c.11bn won | 3–5×

2022 | c.500 | ~5% | None | c.13bn won | 5–8×

2023 | c.500 | ~4% | None | c.15bn won | 8–12×

2024 | c.500–600 | ~4% | None | c.16bn won | 15×+

2025 | TBC | Not announced | Under consideration | c.15.5bn won | Elevated

*Dividend figures and pay-out ratios include estimates based on filings and press reports. P/B ratios are estimated on an intra-year peak basis.*

The central challenge for Samchundang's reform credentials is to demonstrate — simultaneously and in concrete terms — that it can restore disclosure integrity and deliver on shareholder returns. The market acknowledges the company's technological merits and pipeline value. But the broad consensus is that it cannot be held up as a model of KOSDAQ's value-creation programme until both the credibility deficit exposed by the Samchundang incident and the long record of neglecting shareholder returns have been visibly and durably addressed.